Pembrolizumab (pembro) plus olaparib in patients with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): Update of KEYNOTE-365 cohort A with a minimum of 11 months of follow-up for all patients

被引：8
|
作者：
Yu, E. [1 ]
Piulats, J. M. [2 ]
Gravis, G. [3 ]
Fong, P. C. C. [4 ]
Todenhoefer, T. [5 ]
Laguerre, B. [6 ]
Arranz Arija, J. A. [7 ]
Oudard, S. [8 ]
Massard, C. [9 ,10 ]
Stoeckle, M. [11 ]
Nordquist, L. T. [12 ]
Carles, J. [13 ]
Kolinsky, M. P. [14 ]
Augustin, M. [15 ]
Gurney, H. [16 ,17 ]
Tafreshi, A. [18 ]
Li, X. T. [19 ]
Poehlein, C. H. [19 ]
Schloss, C. [19 ]
de Bono, J. S. [20 ]
机构：
[1] Univ Washington, Med Oncol, Seattle, WA 98195 USA
[2] Catalan Inst Oncol, Med Oncol, Barcelona, Spain
[3] Inst Paoli Calmettes, Med Oncol, Paris, France
[4] Auckland City Hosp, Med Oncol, Auckland, New Zealand
[5] Studienpraxis Urol, Urol, Nuertingen, Germany
[6] Ctr Eugene Marquis, Med Oncol, Rennes, France
[7] Gen Univ Hosp Gregorio Maranon, Med Oncol, Madrid, Spain
[8] Hop Europeen Georges Pompidou, Med Oncol, Paris, France
[9] Gustave Roussy Canc Campus, Med Oncol, Villejuif, France
[10] Paris Sud Univ, Villejuif, France
[11] Saarland Univ Hosp, Urol, Homburg, Germany
[12] Urol Canc Ctr, GU Res Network, Med Oncol, Omaha, NE USA
[13] Vall dHebron Univ Hosp, Genitourinary Oncol, Barcelona, Spain
[14] Cross Canc Inst, Med Oncol, Edmonton, AB, Canada
[15] Paracelsus Med Univ, Urol, Nurnberg, Germany
[16] Westmead Hosp, Med Oncol, Sydney, NSW, Australia
[17] Macquarie Univ Hosp, Sydney, NSW, Australia
[18] Univ Wollongong, Med Oncol, Wollongong, NSW, Australia
[19] Merck & Co Inc, Med Oncol, Kenilworth, NJ USA
[20] Royal Marsden NHS Fdn Trust, Med Oncol, London, England
来源：
ANNALS OF ONCOLOGY | 2021年 / 32卷
关键词：
D O I：
10.1016/j.annonc.2021.08.1125
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
612P
引用
收藏
页码：S652 / S653
页数：2
相关论文
共 50 条
  • [1] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort A update
    Arranz Arija, J. A.
    Yu, E. Y.
    Piulats, J. M.
    Gravis, G.
    Laguerre, B.
    Oudard, S.
    Fong, P. C.
    Kolinsky, M. P.
    Augustin, M.
    Todenhofer, T.
    Kam, A. E.
    Gurney, H.
    Tafreshi, A.
    Retz, M.
    Berry, W. R.
    Mar, N.
    Wu, H.
    Qiu, P.
    Schloss, C.
    de Bono, J. S.
    ANNALS OF ONCOLOGY, 2020, 31 : S513 - S514
  • [2] PEMBROLIZUMAB (PEMBRO) PLUS OLAPARIB IN PATIENTS WITH DOCETAXEL-PRETREATED METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC): UPDATED RESULTS FROM KEYNOTE-365 COHORT A WITH A MINIMUM OF 11 MONTHS OF FOLLOW-UP FOR ALL PATIENTS
    Nordquist, Luke T.
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Fong, Peter C. C.
    Todenhoefer, Tilman
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Massard, Christophe
    Stoeckle, Michael
    Carles, Joan
    Kolinsky, Michael Paul
    Augustin, Marinela
    Gurney, Howard
    Tafreshi, Ali
    Li, Xin Tong
    Poehlein, Christian Heinrich
    Schloss, Charles
    de Bono, Johann S.
    JOURNAL OF UROLOGY, 2021, 206 : E417 - E417
  • [3] KEYNOTE-365 cohort A updated results: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castration-resistant prostate cancer (mCRPC)
    Yu, Evan Y.
    Piulats, Josep M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arija, Jose Angel Arranz
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Feyerabend, Susan
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Helen
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (06)
  • [4] Keynote-365 cohort a: Pembrolizumab (pembro) plus olaparib in docetaxel-pretreated patients (pts) with metastatic castrate-resistant prostate cancer (mCRPC).
    Yu, Evan Y.
    Massard, Christophe
    Retz, Margitta
    Tafreshi, Ali
    Carles Galceran, Joan
    Hammerer, Peter
    Fong, Peter C. C.
    Shore, Neal D.
    Joshua, Anthony
    Linch, Mark David
    Gurney, Howard
    Romano, Emanuela
    Augustin, Marinela
    Piulats, Josep M.
    Wu, Haiyan
    Schloss, Charles
    Poehlein, Christian Heinrich
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (07)
  • [5] Pembrolizumab (pembro) plus olaparib in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort A efficacy, safety, and biomarker results.
    Yu, Evan Y.
    Piulats Rodriguez, Jose Maria M.
    Gravis, Gwenaelle
    Laguerre, Brigitte
    Arranz Arija, Jose Angel
    Oudard, Stephane
    Fong, Peter C. C.
    Kolinsky, Michael Paul
    Augustin, Marinela
    Todenhofer, Tilman
    Kam, Audrey E.
    Gurney, Howard
    Tafreshi, Ali
    Retz, Margitta
    Berry, William R.
    Mar, Nataliya
    Wu, Haiyan
    Qiu, Ping
    Schloss, Charles
    De Bono, Johann S.
    JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
  • [6] Pembrolizumab (pembro) plus lenvatinib (lenva) in patients (pts) with docetaxel-pretreated, metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort E.
    Augustin, Marinela
    Laguerre, Brigitte
    Baldini, Capucine
    Zedan, Ahmed H.
    Gonzalez-Billalabeitia, Enrique
    Fong, Peter C. C.
    Zukov, Ruslan
    Hammerer, Peter
    Prentice, Mark
    Shore, Neal D.
    Necchi, Andrea
    Todenhoefer, Tilman
    Kessler, Elizabeth R.
    Kose, Fatih
    Gurney, Howard
    Valderrama, Begona Perez
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    McDermott, Raymond S.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 148 - 148
  • [7] KEYNOTE-365 Cohort A: Pembrolizumab Plus Olaparib in Docetaxel-Pretreated Patients With Metastatic Castrate-Resistant Prostate Cancer
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (04) : 14 - 15
  • [8] Coformulation of pembrolizumab and vibostolimab in patients (pts) with docetaxel-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort G.
    Fong, Peter C. C.
    Kwiatkowski, Mariusz
    Mosca, Alessandra
    Valderrama, Begona Perez
    Huang, Yi-Hsiu
    Zedan, Ahmed H.
    Kuc, Kamil
    Wiechno, Pawel
    Laguerre, Brigitte
    Gonzalez-Billalabeitia, Enrique
    Osipov, Mikhail
    Dede, Didem Sener
    Goh, Jeffrey
    Daugaard, Gedske
    Zhu, Pengfei
    Imai, Kentaro
    Liu, Yingjie
    Arija, Jose Angel Arranz
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (4_SUPPL) : 149 - 149
  • [9] Pembrolizumab (pembro) plus docetaxel and prednisone in patients with abiraterone acetate (abi)- or enzalutamide (enza)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 cohort B update
    Romano, E.
    Sridhar, S. S.
    Kolinsky, M. P.
    Gravis, G.
    Mourey, L.
    Piulats, J. M.
    Berry, W. R.
    Gurney, H.
    Retz, M.
    Appleman, L. J.
    Boegemann, M.
    de Bono, J. S.
    Joshua, A. M.
    Emmenegger, U.
    Conter, H. J.
    Laguerre, B.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S512 - S513
  • [10] Pembrolizumab (pembro) plus enzalutamide (enza) in patients with abiraterone acetate (abi)-pretreated metastatic castration-resistant prostate cancer (mCRPC): KEYNOTE-365 Cohort C update
    Mourey, L.
    Conter, H. J.
    Shore, N.
    Berry, W. R.
    Fong, P. C.
    Piulats, J. M.
    Appleman, L. J.
    Todenhoefer, T.
    Gravis, G.
    Laguerre, B.
    Gurney, H.
    Retz, M.
    Romano, E.
    de Bono, J. S.
    Kam, A. E.
    Emmenegger, U.
    Wu, H.
    Qiu, P.
    Schloss, C.
    Yu, E. Y.
    ANNALS OF ONCOLOGY, 2020, 31 : S516 - S517
12345